Biogen

Revenue rose 3% to $2.74 billion, surpassing Bloomberg consensus of $2.47 billion. Adjusted EPS fell to $3.60 YoY but beat consensus $2.89, while non‑GAAP diluted EPS guidance lifted to $15.85‑$16.85